MyFastRx logo

MyFastRx Review

Best for: Cash-pay patients comfortable with 12-month upfront billing for the lowest compounded-GLP-1 monthly rate.

MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles. Compounded semaglutide runs $169/mo standard, dropping to $99/mo on a 12-month prepay; tirzepatide is $249/mo standard, down to $149/mo on 12 months — all doses priced the same with a SAVE70 first-month promo. It accepts no insurance and ships nationwide; LegitScript-listed and HIPAA-compliant.

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed
7.0
★★★3.5
CompoundedSemaglutideTirzepatideLegitScript VerifiedHIPAA CompliantInsurance CoordinationMulti-Month Bundle DiscountsNationwide Discreet Shipping
$99/mo
Same price at every dose

What the monthly price covers

Medication

Included

Provider visits

Included

Shipping

Included

Lab work

Not disclosed

Coaching

Not disclosed

See plans →

No insurance neededVetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

The Bottom Line

MyFastRx is a solid telehealth option with balanced features and pricing.

Score: 7/10Best for: Cash-pay patients comfortable with 12-month upfront billing for the lowest compounded-GLP-1 monthly rate.From: $99/mo
MyFastRx logo
3.5 / 5
Our editorial rating
Visit MyFastRx

from $99/mo · no insurance needed

MyFastRx at a glance

Type
GLP-1 telehealth provider
Medications
Semaglutide, Tirzepatide
Starting price
$99/mo
Pricing model
Flat — dose increases don't raise the monthly price
What's included
Medication · Consult · Shipping
Availability
All 50 states
FDA status
No FDA warning letter on record

How we scored MyFastRx

Each dimension is scored algorithmically from MyFastRx’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.

Value25%

8.3/10

At $99/mo, MyFastRx runs about 42% below the $170 median for GLP-1 providers. Pricing is flat across doses, so there is no escalation markup as you titrate up.

Effectiveness25%

7.1/10

MyFastRx offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.

User Experience15%

6.4/10

Online intake and platform experience — consult included in the price; 8 platform features disclosed.

Trust & Safety15%

6.3/10

Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-06-06).

Accessibility10%

7.6/10

MyFastRx treats patients in all 50 states. Insurance pathways are offered for eligible patients.

Support10%

4.9/10

MyFastRx provides standard clinician follow-up; no extended coaching or community program is disclosed.

How we verified this MyFastRx review

Last checked 2026-06-06
  • Confirmed current pricing across 4 dose/plan tiers
  • Confirmed availability in all 50 states
  • Confirmed what the monthly price does and doesn't include
  • Checked the FDA warning-letter database for enforcement actions
  • Walked the public intake/checkout flow on the provider's site

Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.

GLP-1 medications MyFastRx offers

Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.

Pricing

All doses (monthly standard)Compounded
$169/mo
semaglutide
12-month bundle (billed upfront)Compounded
$99/mo
semaglutide
All doses (monthly standard)Compounded
$249/mo
tirzepatide
12-month bundle (billed upfront)Compounded
$149/mo
tirzepatide

Ready to get started?

Plans and promotions change often — check MyFastRx's current pricing and active discounts before you decide.

See MyFastRx pricing →

What we like

  • Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
  • LegitScript certified
  • All doses priced the same — no cost escalation as you titrate up
  • First-month promo discount lowers the trial barrier

Watch-outs

  • States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
  • Corporate address and medical director not published
  • Pharmacy partner not named — only 'state-licensed pharmacies'
  • Cash-pay only — no insurance billing
  • Bundle savings require a large upfront commitment (12 months billed at once)

MyFastRx: the cheapest compounded GLP-1 if you'll pay a year upfront

MyFastRx is a cash-pay telehealth platform built around one idea: get you approved fast and reward you for committing long-term. Its headline rate of $99 a month for compounded semaglutide is among the lowest published prices we track — but that number only appears if you prepay a full twelve months at once. Pay month to month and you'll spend considerably more. So the real question isn't whether MyFastRx is cheap; it's whether you're ready to bet a year of treatment on a provider that keeps a lot of its operation undisclosed. For the right patient, the math is genuinely attractive. For everyone else, the trade-offs deserve a hard look.

How the bundle pricing actually works

MyFastRx uses a tiered ladder where the price drops the longer you commit. Compounded semaglutide starts at a standard monthly rate and steps down through three-month and six-month plans to $99 a month on the twelve-month bundle. Compounded tirzepatide follows the same structure at a higher price point, landing in the mid-hundreds per month on the full-year plan. A first-month promo code (SAVE70) knocks the opening payment down to lower the trial barrier.

The catch is right there in the structure: those best-case numbers are billed upfront, all twelve months at once. That's a large single charge to a provider whose pharmacy partner and medical director aren't named publicly. The standard month-to-month rate is real and still reasonable, but it's nowhere near the figure the homepage leads with. For context, the $170 category median sits between MyFastRx's standard and bundle rates — so this provider is a genuine value play only if you go long.

Flat dosing is the underrated win here

One feature that quietly favors patients: every dose costs the same. Many compounded-GLP-1 sellers raise your monthly bill as you titrate up to higher strengths, which punishes you precisely as the medication starts working. MyFastRx prices all doses identically. Whether you're starting low or have climbed to a maintenance dose, your rate doesn't move. Over a year of dose escalation, that flat structure can save real money compared with a provider that charges by strength — and it makes budgeting predictable, which matters when you've already prepaid.

What you actually get

  • Compounded semaglutide or compounded tirzepatide, injectable
  • A doctor consultation included — no separate visit fee
  • Free discreet shipping nationwide
  • The same price at every dose as you titrate up
  • A tiered discount that rewards 3-, 6-, or 12-month commitments

The medications and how they're dispensed

MyFastRx deals exclusively in compounded versions of semaglutide and tirzepatide — the same active ingredients as the brand-name injectables, prepared by a compounding pharmacy rather than the original manufacturer. There's no brand-name Wegovy, Zepbound, or Ozempic option here, and no oral pill; this is injectable compounded medication only. The consultation and shipping are bundled into the price, so the monthly figure is close to your all-in cost rather than a teaser that balloons at checkout.

What MyFastRx will not tell you is which pharmacy makes your medication. The site references 'state-licensed pharmacies' but names no specific 503A or 503B partner. For a compounded product — where the pharmacy IS the quality control — that opacity is a meaningful gap. You're trusting the platform's vetting without being able to verify the source yourself.

Trust and safety: a mixed, medium-confidence picture

On the positive side, MyFastRx is LegitScript-certified, which is a real credential — it means a third party reviewed the operation for compliance with pharmacy and telehealth rules. The platform is HIPAA-compliant and operates as a registered corporate entity. There are no FDA warning letters on file against it in our records, and it claims to work through licensed U.S. providers across all states.

But the disclosure gaps keep this from being a high-confidence pick. The specific states served aren't enumerated. No medical director is named. No corporate address is published. The pharmacy partner is anonymous. None of these is individually disqualifying, but together they mean you're extending more trust than a fully transparent provider would ask for. Our scoring methodology treats undisclosed oversight as a real cost, and MyFastRx pays it. We'd rate the verification here as medium — the pricing is verbatim and the LegitScript listing checks out, but the people and places behind the brand stay in the shadows.

Who should choose it — and who should skip it

Choose MyFastRx if you're a cash-pay patient who has already decided you're in this for the long haul, you're comfortable paying a full year upfront, and the lowest possible monthly rate is your top priority. The flat per-dose pricing and bundled consult make it especially good for someone who expects to titrate to a higher maintenance dose and wants their cost locked in.

Skip it if you want to start month-to-month and see how you respond before committing — the standard rate erases much of the advantage. Skip it if you need insurance billing, since MyFastRx is cash-pay only and won't coordinate coverage. And skip it if undisclosed oversight is a dealbreaker for you: a named pharmacy and a published medical director are things some competitors offer, and if that transparency matters, you can find it elsewhere.

Bottom line

MyFastRx earns its place as a value option for committed, cash-pay GLP-1 patients. The twelve-month bundle rate of $99 for compounded semaglutide is legitimately competitive, and flat dosing is a patient-friendly touch too few providers offer. But the price you see advertised is the long-commitment price, and the company asks for that commitment while keeping its pharmacy, medical leadership, and state footprint private. If you go in clear-eyed — prepaying a year to a LegitScript-listed but partly opaque platform in exchange for a low rate — it can be a smart deal. If any of that gives you pause, a more transparent provider is worth the few extra dollars.

Shopping around? Telos Rx ($49/month) and bmiMD ($99/month) are the nearest alternatives to MyFastRx in our rankings.

Ready to start with MyFastRx?

Starting at $99/month. See current pricing and start your free consultation.

Alternatives to MyFastRx

8.6/ 10
Verified partner

Enhance MD

Best for: lab-monitored compounded GLP-1 with mandatory video visit

★★★★4.3

Editorial score · methodology

$49/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Enhance MD review →
8.5/ 10
Verified partner

Embody

Best for: lowest first-month entry pricing on compounded GLP-1s

★★★★4.3

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Embody review →
8.5/ 10
Verified partner

TrimRx

Best for: best overall value

★★★★4.3

Editorial score · methodology

$179/mo
CompoundedSemaglutide
Get StartedRead full TrimRx review →

Frequently Asked Questions

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Sources

The primary regulatory filings and peer-reviewed studies cited throughout this MyFastRx review:

Sources & methodology — as of July 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy FrameworkU.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)U.S. Food & Drug Administration.
  4. 4.PCAB — Pharmacy Compounding Accreditation Board StandardsAccreditation Commission for Health Care (ACHC) / PCAB.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)Kaiser Family Foundation.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)New England Journal of Medicine.PMID: 33567185.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDAU.S. Food & Drug Administration.
  8. 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDAU.S. Food & Drug Administration.
  9. 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)New England Journal of Medicine.PMID: 35658024.
  10. 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDAU.S. Food & Drug Administration.
  11. 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDAU.S. Food & Drug Administration.
  12. 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)New England Journal of Medicine.PMID: 40334173.

Ready to start with MyFastRx?

Starting at $99/month. See current pricing and start your free consultation.